Fabrazyme helps people with Fabry disease by replacing a missing enzyme. It has been used to treat people with Fabry disease for over 15 years and is backed by the safety and effectiveness shown in clinical studies.
HOW FABRAZYME CAN HELP YOUFabrazyme® (agalsidase beta) is used to treat patients with Fabry disease. Fabrazyme lowers the amount of a substance called globotriaosylceramide (GL-3), which builds up in cells lining the blood vessels of the kidney and certain other cells.
The lowering of GL-3 suggests that Fabrazyme may improve how Fabry disease affects your body; however a relationship of lower GL-3 to specific signs and symptoms of Fabry disease has not been proven.
One goal in the treatment of Fabry disease is to clear and prevent future buildup of a fatty substance called GL-3, which can accumulate in key organs and cause organ damage. If you have been diagnosed, you and your doctor should discuss if treatment is right for you.
Learn about treatment guidelinesSanofi Genzyme's more than 35 year commitment to supporting the rare disease community is designed to support your unique journey. The Copay Assistance program helps qualified individuals pay for eligible expenses.
Learn MoreFabrazyme introduces an external supply of fully functional enzyme into the body. The way it works is not based on the Fabry patient's DNA mutation.
Watch the Video